West Pharmaceutical Services (WST) has had a tumultuous few years. The company's shareholders earned a
17% CAGR over the last five years, with several fluctuations along the way. WST's stock has underperformed compared to competitors recently but saw an upturn with the release of the company's third and fourth quarter results. These earnings releases signaled an increase in their fiscal year 2024 guidance, resulting in optimistic buy recommendations from both
UBS and Citigroup.
WST seems focused on expansion and innovation, unveiling new products like the
PLASCAP Ready-to-Use closures for gene therapy applications and AI solutions to address profitability. Despite this, WST's stock has been dubbed as a bottom-ranked quant stock by UBS and has seen several significant sales, particularly from
Riverbridge Partners LLC and
Bright Rock Capital Management LLC.
WST aims to show its continued industry leadership by attending and presenting at several conferences. It has also strengthened its board with new directors and made key leadership appointments. However, WST's stock saw a dip when it reported lower-than-expected results and reduced guidance, later slashing its 2024 forecasts due to
lower demand.
West Pharmaceutical Services WST News Analytics from Tue, 25 Jan 2022 08:00:00 GMT to Sat, 25 Jan 2025 13:15:44 GMT -
Rating 0
- Innovation 6
- Information 8
- Rumor -6
